Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312904924> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4312904924 abstract "Objective: There are currently no effective treatments for sepsis-induced inflammatory lung injury, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The repositioning of existing drugs is one possible strategy for the treatment of ALI/ARDS. We previously showed that vascular repair and resolution of ALI is dependent upon hypoxia-inducible factor 1 alpha (HIF1a) and forkhead box M1 (FoxM1) in endothelial cells. The aim of this study was to identify a candidate agonist of HIF1a/FoxM1 signaling to treat ALI/ARDS. Approach and Results: First, we adopted a high throughput screening approach of a library of 1200 FDA-approved drugs by using hypoxia response element (HRE)-driven luciferase reporter assays, cell toxicity assays, and molecular analyses of human lung endothelial cells, to identify candidate HIF1 agonists in vitro . One of the top candidate drugs, Rabeprazole (also known as Aciphex), gave rise to dose-dependent increases in HRE luciferase activity without concurrent increases in cell death. Next, we performed dose-response studies of Rabeprazole in a mouse model of sepsis-induced ALI. By treating wild type mice orally with Rabeprazole on 2 consecutive days after endotoxic sepsis challenge, we were able to identify a dose of Rabeprazole that is well tolerated and enhanced vascular repair and resolution of ALI. In timeline studies of murine inflammatory lung injury, we found that Rabeprazole treatment resulted in reductions in lung vascular leakage, edema, and inflammatory cytokine expression during the repair phrase following sepsis-induced ALI. Finally, we used conditional knockout mice to show that Rabeprazole increases vascular repair and resolution of ALI via HIF1a/FoxM1 signaling. Conclusions: Rabeprazole is a HIF1a agonist that improves vascular repair and resolution of sepsis-induced inflammatory lung injury. Rabeprazole represents a promising candidate for repurposing to treat ALI/ARDS." @default.
- W4312904924 created "2023-01-05" @default.
- W4312904924 creator A5020299004 @default.
- W4312904924 creator A5030531487 @default.
- W4312904924 creator A5061188077 @default.
- W4312904924 creator A5069402474 @default.
- W4312904924 creator A5076073719 @default.
- W4312904924 date "2022-05-01" @default.
- W4312904924 modified "2023-10-09" @default.
- W4312904924 title "Abstract 122: Rabeprazole Enhances Vascular Repair And Resolution Of Sepsis-induced Lung Injury Through HIF1/FoxM1 Signaling" @default.
- W4312904924 doi "https://doi.org/10.1161/atvb.42.suppl_1.122" @default.
- W4312904924 hasPublicationYear "2022" @default.
- W4312904924 type Work @default.
- W4312904924 citedByCount "0" @default.
- W4312904924 crossrefType "journal-article" @default.
- W4312904924 hasAuthorship W4312904924A5020299004 @default.
- W4312904924 hasAuthorship W4312904924A5030531487 @default.
- W4312904924 hasAuthorship W4312904924A5061188077 @default.
- W4312904924 hasAuthorship W4312904924A5069402474 @default.
- W4312904924 hasAuthorship W4312904924A5076073719 @default.
- W4312904924 hasConcept C126322002 @default.
- W4312904924 hasConcept C142724271 @default.
- W4312904924 hasConcept C203014093 @default.
- W4312904924 hasConcept C2776348555 @default.
- W4312904924 hasConcept C2777498785 @default.
- W4312904924 hasConcept C2777714996 @default.
- W4312904924 hasConcept C2778384902 @default.
- W4312904924 hasConcept C2779116819 @default.
- W4312904924 hasConcept C2779134260 @default.
- W4312904924 hasConcept C2779559532 @default.
- W4312904924 hasConcept C2780394083 @default.
- W4312904924 hasConcept C3008058167 @default.
- W4312904924 hasConcept C31194975 @default.
- W4312904924 hasConcept C502942594 @default.
- W4312904924 hasConcept C524204448 @default.
- W4312904924 hasConcept C71924100 @default.
- W4312904924 hasConcept C98274493 @default.
- W4312904924 hasConceptScore W4312904924C126322002 @default.
- W4312904924 hasConceptScore W4312904924C142724271 @default.
- W4312904924 hasConceptScore W4312904924C203014093 @default.
- W4312904924 hasConceptScore W4312904924C2776348555 @default.
- W4312904924 hasConceptScore W4312904924C2777498785 @default.
- W4312904924 hasConceptScore W4312904924C2777714996 @default.
- W4312904924 hasConceptScore W4312904924C2778384902 @default.
- W4312904924 hasConceptScore W4312904924C2779116819 @default.
- W4312904924 hasConceptScore W4312904924C2779134260 @default.
- W4312904924 hasConceptScore W4312904924C2779559532 @default.
- W4312904924 hasConceptScore W4312904924C2780394083 @default.
- W4312904924 hasConceptScore W4312904924C3008058167 @default.
- W4312904924 hasConceptScore W4312904924C31194975 @default.
- W4312904924 hasConceptScore W4312904924C502942594 @default.
- W4312904924 hasConceptScore W4312904924C524204448 @default.
- W4312904924 hasConceptScore W4312904924C71924100 @default.
- W4312904924 hasConceptScore W4312904924C98274493 @default.
- W4312904924 hasIssue "Suppl_1" @default.
- W4312904924 hasLocation W43129049241 @default.
- W4312904924 hasOpenAccess W4312904924 @default.
- W4312904924 hasPrimaryLocation W43129049241 @default.
- W4312904924 hasRelatedWork W1966296301 @default.
- W4312904924 hasRelatedWork W1982771665 @default.
- W4312904924 hasRelatedWork W1991303578 @default.
- W4312904924 hasRelatedWork W2075918949 @default.
- W4312904924 hasRelatedWork W2406153264 @default.
- W4312904924 hasRelatedWork W3041276741 @default.
- W4312904924 hasRelatedWork W3125338983 @default.
- W4312904924 hasRelatedWork W3217749975 @default.
- W4312904924 hasRelatedWork W4233147319 @default.
- W4312904924 hasRelatedWork W76543614 @default.
- W4312904924 hasVolume "42" @default.
- W4312904924 isParatext "false" @default.
- W4312904924 isRetracted "false" @default.
- W4312904924 workType "article" @default.